pharmocology

Course Overview

  • Focus on medical interventions.

  • Today’s discussion: Medications.

  • Next class: Surgery interventions.

  • Following class: Behavioral interventions.

Weight Loss Project

  • Upcoming project due date discussed (17th).

  • Feedback from students considered for project due date.

  • Aim to incorporate behavioral interventions before submission:

    • Suggested due: Last day of the semester.

Social Media Presentation

  • Social media help claim presentations may need to be divided across two class periods (April 3rd and April 8th).

  • Each presentation expected to last 10 minutes.

Case Study: Robert

  • Profile:

    • Older individual with a BMI of 33 (obese).

    • Suffers from hypertension and has been inactive.

    • Concerns: knee pain and balance issues.

  • Considerations for Intervention:

    • Need a tailored approach due to hypertension; adjustments required.

    • Focus on improving fitness, strength, and balance cautiously.

Physical Activity Recommendations

  • Activity Type:

    • Start with light-intensity exercises due to age and health concerns.

    • Suggested activities:

    • Walking on a treadmill (holding rails).

    • Using an elliptical machine.

  • Session Duration:

    • Initial recommendation: 20 minutes.

  • Gradual increase to recommended 5-7 days a week after building a habit.

Contraindications and Considerations

  • Importance of consideration of age (risk factor considerations).

  • Potential pain management needs for knee pain.

  • Coordination with medications that Robert might be taking (e.g., beta blockers).

  • Understand contraindications and health implications in fitness plans.

Pharmacological Interventions for Obesity and Diabetes

  • Focus on GLP-1 receptor agonists, specifically Ozempic (Semaglutide).

  • Shift in terminology from "anti-obesity medications" to "obesity management medications (OMM)".

Reasons for Medication Use

  • Compliance and ease of medication regimens compared to lifestyle changes.

  • Management of obesity-related comorbidities aims to improve the quality of life and mitigate risks.

  • Medications mainly target energy intake by reducing appetite:

    • Affecting hunger signals and appetite-regulation hormones.

    • Some may have an impact on metabolic rate.

Ethical Considerations

  • Discussion on appropriate regulation for those with eating disorders who could misuse these medications.

  • Concerns about the stigma attached to “anti-obesity” terminology.

Prescription Guidelines for Medications

  • Primarily for those classified as obese (BMI >= 30).

  • Medications considered when associated with diseases such as diabetes.

  • Historical Context:

    • Medications in use since 1890s, with strict criteria established in the 1990s.

    • Development time for new drugs averages 15 years.

    • History demonstrates many previous medications withdrawn due to complications and side effects (including severe ones such as blindness).

Overview of Specific Medications

  • Notable medications include:

    • Orlistat: Prevents fat absorption, causes GI issues and discomfort, rarely prescribed now due to effects.

    • GLP-1 Agonists: Example: Semaglutide, recently popular and effective.

    • Zelaglutide and Tirzepatide: Newer medications with shared mechanisms of action.

    • Medications often developed for diabetes may be repurposed for obesity treatment.

Mechanisms of Action

  • GLP-1:

    • Naturally produced in the body, enhancing insulin secretion, reducing appetite, and delaying gastric emptying.

    • Act on the brain, pancreas, and digestive system to manage appetite and blood sugar levels.

    • Must be injected rather than taken orally due to breakdown in the stomach.

  • Sympathetic Nervous System (SNS) Activation Effects:

    • Increased metabolism through norepinephrine release; can lead to side effects including insomnia, dry mouth, and increased heart rate.

Side Effects and Concerns

  • Common side effects associated with GLP-1 agonists:

    • Nausea and vomiting are prevalent among users.

    • Risk of gallbladder issues and potential for depression.

    • Nutritional deficiencies can develop over prolonged use.

Long-Term Use and Sustainability Issues

  • While effective, continual reliance on medications may not prevent weight regain once discontinued.

  • Medication assists in weight loss but does not inherently change lifestyle habits.

  • Necessitates incorporation of consistent dietary and physical activity modifications to sustain weight loss.

  • Wider availability of medications may outstrip accessibility depending on economic means of individuals requiring them.

Research on Additional Uses

  • Potential for obesity management medications, specifically GLP-1, in treating related comorbidities (e.g., osteoarthritis).

  • Ongoing research on effectiveness of GLP-1 in cancer prevention associated with obesity.

Final Thoughts

  • Long-term studies still required to assess the comprehensive efficacy and safety of these pharmacotherapies.

  • Lifestyle change integration is essential for sustainable weight management and health.

  • Overall effectiveness of lifestyle modifications alongside pharmacological interventions is encouraged.